Skip to main content

Table 1 Baseline characteristics of the randomized controlled trial population, according to treatment arm.

From: Effects of combined deferiprone with deferoxamine on right ventricular function in thalassaemia major

  Combined Deferoxamine p-value
Number of patients 32 33 -
Age (years) 28.8 ± 4.2 28.7 ± 5.3 0.9
Gender (male) 14 (44%) 13 (39%) 0.5
Body surface area 1.53 ± 0.15 1.56 ± 0.16 0.5
Heart rate 78 ± 10 81 ± 16 0.3
Deferoxamine dose (mg/kg/day) 40.6 ± 13.2 (5 days/week) a 1.0
CMR measures    
Myocardial T2* 11.7 (0.08) 12.4 (0.11) 0.3
Liver T2* 4.9 (0.52) 4.2 (0.62) 0.5
RVEDV (mL) 129.5 ± 30.8 131.8 ± 34.4 0.8
RVESV (ml) 52.5 ± 17.5 52.3 ± 18.5 1.0
RVEF (%) 60.2 ± 7.2 61.0 ± 7.1 0.7
Echo measures    
PAP (mmHg) 22.3 ± 5.0 20.9 ± 5.4 0.4
Blood measures    
Transfusional red blood cell input (mL/kg/year) 133.4 ± 34.9 130.2 ± 38.6 0.7
Haemoglobin (g/L) 106 ± 9.6 102 ± 9.5 0.1
Hepatitis C positive 23 (72%) 26 (79%) 0.4
Serum ferritin (μg/L) 1574 (11) 1379 (10) 0.5
BNP (pmol/L) 13.6 (5.6, 30.1) 15.2 (7.3, 26.2) 0.7
Creatinine (mg/dL) 0.77 ± 0.21 0.74 ± 0.23 0.6
Cardiac medication    
Any 5 (16%) 8 (24%) 0.4
Digoxin 3 (9%) 4 (12%) 0.7
ACEi/ARB 5 (16%) 8 (24%) 0.4
Diuretics 3 (9%) 5 (15%) 0.5
  1. Values are presented as n (%), mean ± SD, geometric mean (coefficient of variation), or as median (25th - 75th percentile). RV = right ventricular; EDV = end-diastolic volume; ESV = end-systolic volume; PAP = pulmonary artery systolic pressure; BNP = B-type natriuretic peptide. ACEi = angiotensin-converting enzyme inhibitors; ARB = angiotensin II receptor blockers.